Pictet Asset Management SA decreased its position in shares of Zai Lab Limited (NASDAQ:ZLAB – Get Rating) by 9.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,812 shares of the company’s stock after selling 8,062 shares during the period. Pictet Asset Management SA’s holdings in Zai Lab were worth $2,837,000 at the end of the most recent quarter.
Several other large investors have also recently added to or reduced their stakes in ZLAB. E Fund Management Hong Kong Co. Ltd. increased its position in Zai Lab by 138.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 45,213 shares of the company’s stock worth $1,939,000 after buying an additional 26,250 shares during the period. Aigen Investment Management LP grew its holdings in shares of Zai Lab by 56.0% during the 1st quarter. Aigen Investment Management LP now owns 5,502 shares of the company’s stock worth $242,000 after purchasing an additional 1,974 shares in the last quarter. Zeal Asset Management Ltd grew its holdings in shares of Zai Lab by 387.1% during the 1st quarter. Zeal Asset Management Ltd now owns 351,829 shares of the company’s stock worth $15,234,000 after purchasing an additional 279,599 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in shares of Zai Lab by 38.6% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 29,682 shares of the company’s stock worth $1,305,000 after purchasing an additional 8,268 shares in the last quarter. Finally, Teacher Retirement System of Texas grew its holdings in shares of Zai Lab by 62.1% during the 1st quarter. Teacher Retirement System of Texas now owns 96,971 shares of the company’s stock worth $4,265,000 after purchasing an additional 37,140 shares in the last quarter.
Insider Activity at Zai Lab
In other news, insider Harald Reinhart sold 1,854 shares of Zai Lab stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $40.00, for a total transaction of $74,160.00. Following the sale, the insider now directly owns 24,861 shares of the company’s stock, valued at $994,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.26% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Zai Lab Stock Down 1.6 %
NASDAQ:ZLAB opened at $34.96 on Monday. The stock’s 50-day simple moving average is $34.12 and its 200 day simple moving average is $36.13. The firm has a market capitalization of $3.42 billion, a PE ratio of -5.62 and a beta of 0.92. Zai Lab Limited has a twelve month low of $20.98 and a twelve month high of $85.82.
Zai Lab Company Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors.
- Get a free copy of the StockNews.com research report on Zai Lab (ZLAB)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.